一个罕见的X因子缺乏病例,由酸诱导
Pierre-Antonin Rigon1, Vincent Ernest2
1Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Marseille, France.
Research and practice in thrombosis and haemostasis
|April 10, 2025
概括
酸 (VPA) 很少会导致获得的X因子缺乏症 (FXD),导致严重出血. 这一案例凸显了对VPA诱导的血液静止障碍和抗FX抗体的警需要.
科学领域:
- 血液学 血液学 血液学
- 临床药理学 临床药理学
- 内部医学 内部医学
背景情况:
- 缺乏X因子 (FXD) 会破坏凝血,导致严重出血.
- 遗传性FXD是罕见的 (500,000分之一);获得的FXD是不常见的,通常与轻链氨基粉症或某些药物有关.
研究的目的:
- 报告一种罕见的,由酸 (VPA) 诱导的获得性FXD病例.
- 要突出VPA诱导的FXD与抗FX抗体的关联.
主要方法:
- 一个65岁的男性患有慢性病和2型糖尿病的案例介绍.
- 患者因而接受VPA治疗,导致严重的FXD (活性<2U/L) 和出血.
- 给予FX替代疗法;停止使用VPA,并监测FX活动.
主要成果:
- 患者经历了严重的出血,需要进行FX替代治疗.
- 在停止使用VPA后9天内,FX活性得到改善,这表明药物诱导的效应.
- 在患者身上发现了抗FX抗体.
结论:
- 临床医生必须意识到与瓦尔酸相关的潜在的血液静止障碍.
- 这一案例强调了在接受VPA治疗的患者中监测凝血的重要性,特别是如果发生出血.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
Disorders of Hemostasis
658
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
658
Extrinsic and Intrinsic Pathways of Hemostasis
4.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.2K
Mania and Antimanic Drugs: Overview
106
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
52
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
52


